Get the Stockscreener App
8.61
0.69%
-0.06
After Hours:
8.61
Kyverna Therapeutics Inc stock is traded at $8.61, with a volume of 979.62K.
It is down -0.69% in the last 24 hours and down -4.97% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$8.67
Open:
$8.75
24h Volume:
979.62K
Relative Volume:
1.11
Market Cap:
$523.45M
Revenue:
-
Net Income/Loss:
$-161.31M
P/E Ratio:
-2.3555
EPS:
-3.6553
Net Cash Flow:
$-154.85M
1W Performance:
-1.03%
1M Performance:
-4.97%
6M Performance:
+12.11%
1Y Performance:
+279.30%
1-Day Range:
$8.24
$8.99
1-Week Range:
$8.24
$9.09
52-Week Range:
$2.4266
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.61 | 527.09M | 0 | -161.31M | -154.85M | -3.6553 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
KYTX News | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
Kyverna begins rolling BLA submission for MIV-CEL - MSN
Kyverna Therapeutics appoints Greg Martini as CFO - MSN
Kyverna Therapeutics (KYTX) grants CFO Martini 325,000 stock options - Stock Titan
CFO Gregory Martini (KYTX) listed as insider in Kyverna Form 3 - Stock Titan
KYTX: Transformative CAR-T therapy for SPS nears launch, with expansion into MG and MS underway - TradingView
Kyverna Therapeutics Appoints Greg Martini as CFO to Drive Commercial Growth and Advance CAR T-Cell Therapy for Autoimmune Diseases - Minichart
Kyverna appoints Greg Martini as chief financial officer - Investing.com UK
Kyverna appoints Greg Martini as chief financial officer By Investing.com - Investing.com South Africa
Kyverna Therapeutics Appoints Greg Martini CFO Ahead of Potential Commercial Launch - citybiz
Kyverna Therapeutics Names Greg Martini CFO - Moomoo
Kyverna Therapeutics names Greg Martini as chief financial officer - marketscreener.com
Kyverna Therapeutics Names Greg Martini As Chief Financial Officer - TradingView
Kyverna Therapeutics Names Gregory Martini as New CFO - TipRanks
Kyverna Therapeutics Appoints Greg Martini as Chief Financial Officer - Quiver Quantitative
New Kyverna (Nasdaq: KYTX) CFO Greg Martini receives cash and equity package - Stock Titan
Press Release: Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - Moomoo
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - Yahoo Finance
Kyverna rises on new mid-stage trial data for myasthenia gravis therapy - MSN
Press Releases about Kyverna Therapeutics, Inc.Common Stock - The Chronicle-Journal
KYTX Maintained by HC Wainwright & Co. -- Price Target Raised to $25 - GuruFocus
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Raises Target Price to $25 - Moomoo
KYTX Stock Price, Quote & Chart | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks making the biggest moves today - MSN
Kyverna Therapeutics files $300M mixed securities shelf - MSN
Kyverna Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Watch Kyverna discuss autoimmune cell therapies at two live webcasts - Stock Titan
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B - BioPharma Dive
Kyverna Therapeutics, Inc. Stock 12‑Month Price Target Cut to $29.4, Implies 187% Upside - TradingView
Wells Fargo Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Kyverna initiates rolling BLA submission for autoimmune CAR T - Investing.com UK
Kyverna Therapeutics 1Q Loss/Shr 66c >KYTX - Moomoo
Kyverna Therapeutics : Investor Presentation – May 2026 - marketscreener.com
Kyverna initiates rolling BLA submission for autoimmune CAR T By Investing.com - Investing.com South Africa
TradingKey - TradingKey
Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis - Fierce Biotech
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results - The Manila Times
Kyverna Therapeutics Begins BLA Submission and Releases First Quarter 2026 Financial Results - geneonline.com
[10-Q] Kyverna Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Kyverna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Kyverna Therapeutics (NASDAQ: KYTX) advances miv-cel SPS BLA and reports Q1 2026 results - Stock Titan
Kyverna Therapeutics Announces Initiation of Rolling SPS - GlobeNewswire
Number of shareholders of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView
Kyverna Therapeutics (KYTX) stock surges 24% after hours: Why is it moving? - MSN
KYTX stock soars after hours: What’s driving the rally? - MSN
RFG Advisory LLC Acquires Shares of 445,200 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Kyverna Therapeutics (KYTX) awards CCO 300,000 stock options - Stock Titan
Kyverna Therapeutics (KYTX) Chief Commercial Officer listed on Form 3 - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):